Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of June 30, 2025, with the inclusion of Jiangsu Hengrui Medicine Co., Ltd. (02617) in the Hang Seng Composite Index, effective after market close on September 5 and starting September 8 [1] - According to Huatai Securities research, Jiangsu Hengrui Medicine Co., Ltd. may be included in the Stock Connect program due to meeting various criteria including market capitalization, liquidity, and listing duration [1] Group 2 - Jiangsu Hengrui Medicine Co., Ltd. announced that its self-developed multi-target kinase inhibitor, TT-00420, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer [1] - The company stated that TT-00420 is currently in global Phase III registration trials, targeting FGFR/VEGFR, JAK, and Aurora kinases to exert anti-tumor effects, with clinical trials in the U.S. and China showing potential efficacy in treating various solid tumors [1]
药捷安康-B(02617)获纳入恒生综合指数 有望成为港股通标的